Loading…
Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review
Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, r...
Saved in:
| Published in: | Metabolic brain disease 2020-10, Vol.35 (7), p.1067-1075 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783 |
| container_end_page | 1075 |
| container_issue | 7 |
| container_start_page | 1067 |
| container_title | Metabolic brain disease |
| container_volume | 35 |
| creator | Meléndez-Flores, Jesús D. Millán-Alanís, Juan Manuel González-Martínez, Adrián Álvarez-Villalobos, Neri Alejandro Estrada-Bellmann, Ingrid |
| description | Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, reports on the effect of their use have been heterogeneous. We aimed to synthesize the available scientific evidence which assesses the effect of glitazone use in type 2 diabetes patients on PD incidence. A systematic review was performed on multiple electronic databases. Considered for inclusion were studies that assessed the incidence of PD in type 2 diabetes glitazone users. Two reviewers worked independently and in duplicate to assess all studies, extract information and assess the methodological quality in each included study. Four high quality retrospective cohorts fulfilled inclusion criteria. Comparison groups varied across studies. In each study, incidence of PD was lower in glitazone-exposed patients compared to their respective comparison group. Pooled analysis showed lesser risk of PD in ever versus never glitazone users (RR 0.75 [95% C.I. 0.67–0.85;
p
|
| doi_str_mv | 10.1007/s11011-020-00568-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398161096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2440323810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783</originalsourceid><addsrcrecordid>eNp9kcFuFSEYhYnR2Gv1BVwYEjduRn9ggJmVaapWkya60DVhLv-01BkYgWlTV_oYfT2fRK63auLCFYHznfMDh5DHDJ4zAP0iMwaMNcChAZCqa-QdsmFSi0YLJe-SDXSdbHTbwwF5kPMFAAjJ-vvkQHChRKv5hnx_FTHTs8kX-zUGpCWhLTOGQs_tJVJLU5yQxkDLOdIl4WWVfN3GkX6w6bMPOYYf324ydT6jzUh9oNatU6kHdsDit3SJyzrZneslPaL5Ohec7U6oaR6vHpJ7o50yPrpdD8mnN68_Hr9tTt-fvDs-Om22QsvSqL5vtRiUHjrGUNanWDYCaqYcStTW8dGKvufMDU7BwLUcWqd07yzTWulOHJJn-9wlxS8r5mJmn7c4TTZgXLPhou-YYtCrij79B72Iawr1doa3LdTf6xhUiu-pbYo5JxzNkvxs07VhYHYFmX1BphZkfhVkZDU9uY1ehxndH8vvRiog9kCuUjjD9Hf2f2J_Am2inNc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440323810</pqid></control><display><type>article</type><title>Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review</title><source>Springer Nature</source><creator>Meléndez-Flores, Jesús D. ; Millán-Alanís, Juan Manuel ; González-Martínez, Adrián ; Álvarez-Villalobos, Neri Alejandro ; Estrada-Bellmann, Ingrid</creator><creatorcontrib>Meléndez-Flores, Jesús D. ; Millán-Alanís, Juan Manuel ; González-Martínez, Adrián ; Álvarez-Villalobos, Neri Alejandro ; Estrada-Bellmann, Ingrid</creatorcontrib><description>Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, reports on the effect of their use have been heterogeneous. We aimed to synthesize the available scientific evidence which assesses the effect of glitazone use in type 2 diabetes patients on PD incidence. A systematic review was performed on multiple electronic databases. Considered for inclusion were studies that assessed the incidence of PD in type 2 diabetes glitazone users. Two reviewers worked independently and in duplicate to assess all studies, extract information and assess the methodological quality in each included study. Four high quality retrospective cohorts fulfilled inclusion criteria. Comparison groups varied across studies. In each study, incidence of PD was lower in glitazone-exposed patients compared to their respective comparison group. Pooled analysis showed lesser risk of PD in ever versus never glitazone users (RR 0.75 [95% C.I. 0.67–0.85;
p
< .0001; I
2
= 0]). Our pooled analysis showed lesser risk of PD in glitazone versus non glitazone users, however, we advise to take results with caution since results are non-adjusted to possible confounding variables, furthermore, different glitazone-exposure time, follow up and comparison groups are aspects that also need to be pointed out. More clinical research focused on glitazone use and its relation with PD is needed, as this could result in new potential treatment modalities.</description><identifier>ISSN: 0885-7490</identifier><identifier>EISSN: 1573-7365</identifier><identifier>DOI: 10.1007/s11011-020-00568-5</identifier><identifier>PMID: 32363472</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antidiabetics ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus - drug therapy ; Health services ; Humans ; Hypoglycemic Agents - therapeutic use ; Incidence ; Information processing ; Insulin ; Metabolic Diseases ; Morris Review Article ; Movement disorders ; Neurodegenerative diseases ; Neurology ; Neuroprotection ; Neurosciences ; Oncology ; Parkinson Disease - epidemiology ; Parkinson Disease - prevention & control ; Parkinson's disease ; Patients ; Quality assessment ; Risk assessment ; Sensitizing ; Systematic review ; Thiazolidinediones - therapeutic use</subject><ispartof>Metabolic brain disease, 2020-10, Vol.35 (7), p.1067-1075</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783</citedby><cites>FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783</cites><orcidid>0000-0002-1995-6593 ; 0000-0001-5583-2582 ; 0000-0002-7812-0462 ; 0000-0001-5208-1429 ; 0000-0001-5252-3637</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32363472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meléndez-Flores, Jesús D.</creatorcontrib><creatorcontrib>Millán-Alanís, Juan Manuel</creatorcontrib><creatorcontrib>González-Martínez, Adrián</creatorcontrib><creatorcontrib>Álvarez-Villalobos, Neri Alejandro</creatorcontrib><creatorcontrib>Estrada-Bellmann, Ingrid</creatorcontrib><title>Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review</title><title>Metabolic brain disease</title><addtitle>Metab Brain Dis</addtitle><addtitle>Metab Brain Dis</addtitle><description>Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, reports on the effect of their use have been heterogeneous. We aimed to synthesize the available scientific evidence which assesses the effect of glitazone use in type 2 diabetes patients on PD incidence. A systematic review was performed on multiple electronic databases. Considered for inclusion were studies that assessed the incidence of PD in type 2 diabetes glitazone users. Two reviewers worked independently and in duplicate to assess all studies, extract information and assess the methodological quality in each included study. Four high quality retrospective cohorts fulfilled inclusion criteria. Comparison groups varied across studies. In each study, incidence of PD was lower in glitazone-exposed patients compared to their respective comparison group. Pooled analysis showed lesser risk of PD in ever versus never glitazone users (RR 0.75 [95% C.I. 0.67–0.85;
p
< .0001; I
2
= 0]). Our pooled analysis showed lesser risk of PD in glitazone versus non glitazone users, however, we advise to take results with caution since results are non-adjusted to possible confounding variables, furthermore, different glitazone-exposure time, follow up and comparison groups are aspects that also need to be pointed out. More clinical research focused on glitazone use and its relation with PD is needed, as this could result in new potential treatment modalities.</description><subject>Antidiabetics</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Health services</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Incidence</subject><subject>Information processing</subject><subject>Insulin</subject><subject>Metabolic Diseases</subject><subject>Morris Review Article</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Neuroprotection</subject><subject>Neurosciences</subject><subject>Oncology</subject><subject>Parkinson Disease - epidemiology</subject><subject>Parkinson Disease - prevention & control</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Quality assessment</subject><subject>Risk assessment</subject><subject>Sensitizing</subject><subject>Systematic review</subject><subject>Thiazolidinediones - therapeutic use</subject><issn>0885-7490</issn><issn>1573-7365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kcFuFSEYhYnR2Gv1BVwYEjduRn9ggJmVaapWkya60DVhLv-01BkYgWlTV_oYfT2fRK63auLCFYHznfMDh5DHDJ4zAP0iMwaMNcChAZCqa-QdsmFSi0YLJe-SDXSdbHTbwwF5kPMFAAjJ-vvkQHChRKv5hnx_FTHTs8kX-zUGpCWhLTOGQs_tJVJLU5yQxkDLOdIl4WWVfN3GkX6w6bMPOYYf324ydT6jzUh9oNatU6kHdsDit3SJyzrZneslPaL5Ohec7U6oaR6vHpJ7o50yPrpdD8mnN68_Hr9tTt-fvDs-Om22QsvSqL5vtRiUHjrGUNanWDYCaqYcStTW8dGKvufMDU7BwLUcWqd07yzTWulOHJJn-9wlxS8r5mJmn7c4TTZgXLPhou-YYtCrij79B72Iawr1doa3LdTf6xhUiu-pbYo5JxzNkvxs07VhYHYFmX1BphZkfhVkZDU9uY1ehxndH8vvRiog9kCuUjjD9Hf2f2J_Am2inNc</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Meléndez-Flores, Jesús D.</creator><creator>Millán-Alanís, Juan Manuel</creator><creator>González-Martínez, Adrián</creator><creator>Álvarez-Villalobos, Neri Alejandro</creator><creator>Estrada-Bellmann, Ingrid</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1995-6593</orcidid><orcidid>https://orcid.org/0000-0001-5583-2582</orcidid><orcidid>https://orcid.org/0000-0002-7812-0462</orcidid><orcidid>https://orcid.org/0000-0001-5208-1429</orcidid><orcidid>https://orcid.org/0000-0001-5252-3637</orcidid></search><sort><creationdate>20201001</creationdate><title>Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review</title><author>Meléndez-Flores, Jesús D. ; Millán-Alanís, Juan Manuel ; González-Martínez, Adrián ; Álvarez-Villalobos, Neri Alejandro ; Estrada-Bellmann, Ingrid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antidiabetics</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Health services</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Incidence</topic><topic>Information processing</topic><topic>Insulin</topic><topic>Metabolic Diseases</topic><topic>Morris Review Article</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Neuroprotection</topic><topic>Neurosciences</topic><topic>Oncology</topic><topic>Parkinson Disease - epidemiology</topic><topic>Parkinson Disease - prevention & control</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Quality assessment</topic><topic>Risk assessment</topic><topic>Sensitizing</topic><topic>Systematic review</topic><topic>Thiazolidinediones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meléndez-Flores, Jesús D.</creatorcontrib><creatorcontrib>Millán-Alanís, Juan Manuel</creatorcontrib><creatorcontrib>González-Martínez, Adrián</creatorcontrib><creatorcontrib>Álvarez-Villalobos, Neri Alejandro</creatorcontrib><creatorcontrib>Estrada-Bellmann, Ingrid</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolic brain disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meléndez-Flores, Jesús D.</au><au>Millán-Alanís, Juan Manuel</au><au>González-Martínez, Adrián</au><au>Álvarez-Villalobos, Neri Alejandro</au><au>Estrada-Bellmann, Ingrid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review</atitle><jtitle>Metabolic brain disease</jtitle><stitle>Metab Brain Dis</stitle><addtitle>Metab Brain Dis</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>35</volume><issue>7</issue><spage>1067</spage><epage>1075</epage><pages>1067-1075</pages><issn>0885-7490</issn><eissn>1573-7365</eissn><abstract>Lately, focus on the relation between Parkinson’s disease (PD) and Diabetes has risen greatly, as neuroprotective properties have been attributed to insulin use. Several studies have assessed the effect of glitazones, an insulin-sensitizing agent, in diabetic population on PD future risk. However, reports on the effect of their use have been heterogeneous. We aimed to synthesize the available scientific evidence which assesses the effect of glitazone use in type 2 diabetes patients on PD incidence. A systematic review was performed on multiple electronic databases. Considered for inclusion were studies that assessed the incidence of PD in type 2 diabetes glitazone users. Two reviewers worked independently and in duplicate to assess all studies, extract information and assess the methodological quality in each included study. Four high quality retrospective cohorts fulfilled inclusion criteria. Comparison groups varied across studies. In each study, incidence of PD was lower in glitazone-exposed patients compared to their respective comparison group. Pooled analysis showed lesser risk of PD in ever versus never glitazone users (RR 0.75 [95% C.I. 0.67–0.85;
p
< .0001; I
2
= 0]). Our pooled analysis showed lesser risk of PD in glitazone versus non glitazone users, however, we advise to take results with caution since results are non-adjusted to possible confounding variables, furthermore, different glitazone-exposure time, follow up and comparison groups are aspects that also need to be pointed out. More clinical research focused on glitazone use and its relation with PD is needed, as this could result in new potential treatment modalities.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32363472</pmid><doi>10.1007/s11011-020-00568-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1995-6593</orcidid><orcidid>https://orcid.org/0000-0001-5583-2582</orcidid><orcidid>https://orcid.org/0000-0002-7812-0462</orcidid><orcidid>https://orcid.org/0000-0001-5208-1429</orcidid><orcidid>https://orcid.org/0000-0001-5252-3637</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-7490 |
| ispartof | Metabolic brain disease, 2020-10, Vol.35 (7), p.1067-1075 |
| issn | 0885-7490 1573-7365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398161096 |
| source | Springer Nature |
| subjects | Antidiabetics Biochemistry Biomedical and Life Sciences Biomedicine Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus - drug therapy Health services Humans Hypoglycemic Agents - therapeutic use Incidence Information processing Insulin Metabolic Diseases Morris Review Article Movement disorders Neurodegenerative diseases Neurology Neuroprotection Neurosciences Oncology Parkinson Disease - epidemiology Parkinson Disease - prevention & control Parkinson's disease Patients Quality assessment Risk assessment Sensitizing Systematic review Thiazolidinediones - therapeutic use |
| title | Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A55%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20glitazone%20treatment%20have%20a%20role%20on%20the%20prevention%20of%20Parkinson%E2%80%99s%20disease%20in%20adult%20diabetic%20population?%20A%20systematic%20review&rft.jtitle=Metabolic%20brain%20disease&rft.au=Mel%C3%A9ndez-Flores,%20Jes%C3%BAs%20D.&rft.date=2020-10-01&rft.volume=35&rft.issue=7&rft.spage=1067&rft.epage=1075&rft.pages=1067-1075&rft.issn=0885-7490&rft.eissn=1573-7365&rft_id=info:doi/10.1007/s11011-020-00568-5&rft_dat=%3Cproquest_cross%3E2440323810%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-699473b67b811e5003a1f0e716de5e7ad2fa39921dbd60b275b4d679da1776783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2440323810&rft_id=info:pmid/32363472&rfr_iscdi=true |